XML 76 R52.htm IDEA: XBRL DOCUMENT
v3.20.2

Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details) - USD ($) $ in Millions |  | 3 Months Ended | 6 Months Ended
--- | --- | --- | ---
Apr. 01, 2019 | Jun. 28, 2020 | Jun. 30, 2019 | Jun. 28, 2020 | Jun. 30, 2019
Segment Reporting Information [Line Items] |  |  |  |  |
Percentage Change In Sales By Geographic Area |  | (10.80%) |  | (3.80%) |
Sales to customers |  | $ 18,336 | $ 20,562 | $ 39,027 | $ 40,583
Percentage Change in Operating Income Loss |  | (44.00%) |  | (8.80%) |
Earnings before provision for taxes on income |  | $ 3,940 | 7,041 | $ 10,449 | 11,463
In-process research and development |  | 6 | 0 | 6 | 890
Reversal of contingent consideration |  |  |  | 983 | 0
Restructuring charges |  | 61 | 57 | 119 | 93
Consumer Health* |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to customers |  | 3,296 | 3,544 | 6,921 | 6,862
Litigation expense |  | 600 | 200 | 600 | 200
PHARMACEUTICAL |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to customers |  | 10,752 | 10,529 | 21,886 | 20,773
In-process research and development |  |  |  |  | 900
Litigation expense |  |  |  |  | 400
Research and Development Expense |  |  |  |  | 300
Medical Devices |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to customers |  | 4,288 | 6,489 | 10,220 | 12,948
Restructuring charges |  | 100 | 100 | 200 | 200
Litigation expense |  |  | 200 |  | 300
Operating Segments |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Total Segment Operating Income |  | $ 4,192 | 7,272 | $ 10,821 | 11,841
Percentage Change in Operating Income Loss |  | (42.40%) |  | (8.60%) |
Operating Segments | Consumer Health* |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Total Segment Operating Income |  | $ 32 | 406 | $ 802 | 1,147
Percentage Change in Operating Income Loss |  | (92.10%) |  | (30.10%) |
Amortization |  | $ 100 | 100 | $ 200 | 200
Operating Segments | PHARMACEUTICAL |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Total Segment Operating Income |  | $ 4,514 | 3,677 | $ 8,348 | 6,008
Percentage Change in Operating Income Loss |  | 22.80% |  | 38.90% |
Amortization |  | $ 800 | 800 | $ 1,600 | 1,600
Unrealized Gain (Loss) on Securities |  | 500 | 200 | 200 | 300
Operating Segments | Medical Devices |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Total Segment Operating Income |  | (354) | 3,189 | $ 1,671 | 4,686
Percentage Change in Operating Income Loss |  |  |  | (64.30%) |
Amortization |  | 200 | 200 | $ 500 | 500
Corporate, Non-Segment |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Total Segment Operating Income |  | $ 252 | 231 | 372 | 378
Ci:z Holdings Co. Ltd. | Consumer Health* |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Gain on sale of equity investments |  |  | 300 |  |
Auris Health |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Reversal of contingent consideration |  |  |  | $ 983 |
United States |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Percentage Change In Sales By Geographic Area |  | (8.30%) |  | (1.40%) |
Sales to customers |  | $ 9,539 | 10,403 | $ 20,238 | 20,532
United States | Consumer Health* |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to customers |  | 1,557 | 1,537 | 3,297 | 2,975
United States | PHARMACEUTICAL |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to customers |  | 6,120 | 5,783 | 12,181 | 11,365
United States | Medical Devices |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to customers |  | $ 1,862 | 3,083 | $ 4,760 | 6,192
Europe |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Percentage Change In Sales By Geographic Area |  | (14.20%) |  | (4.80%) |
Sales to customers |  | $ 4,063 | 4,733 | $ 8,890 | 9,342
Western Hemisphere, excluding U.S. |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Percentage Change In Sales By Geographic Area |  | (22.10%) |  | (10.90%) |
Sales to customers |  | $ 1,133 | 1,455 | $ 2,635 | 2,958
Asia-Pacific, Africa |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Percentage Change In Sales By Geographic Area |  | (9.30%) |  | (6.30%) |
Sales to customers |  | $ 3,601 | 3,971 | $ 7,264 | 7,751
AdvancedSterilizationProducts |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Gain from divestiture of business | $ 2,000 |  |  |  |
AdvancedSterilizationProducts | Medical Devices |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Gain from divestiture of business |  |  | $ 2,000 |  | $ 2,000
Other Income | Auris Health |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Reversal of contingent consideration |  | $ 1,000 |  |  |
Other Income | Auris Health | Medical Devices |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Reversal of contingent consideration |  |  |  | $ 1,000 |

X
- Definition Percentage change in operating income loss. + References No definition available. + Details
Name: | jnj_PercentageChangeInOperatingIncomeLoss
Namespace Prefix: | jnj_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage change in sales by geographic area. + References No definition available. + Details
Name: | jnj_PercentageChangeInSalesByGeographicArea
Namespace Prefix: | jnj_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 + Details
Name: | us-gaap_AdjustmentForAmortization
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 4 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1B -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684 + Details
Name: | us-gaap_GainLossOnSaleOfBusiness
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The difference between the carrying value and the sale price of equity securities, not separately or otherwise categorized as trading or available-for-sale. This element includes investments in which the entity holds a small ownership stake (generally, less than 20% of the shares outstanding) and cannot exert significant influence. + References No definition available. + Details
Name: | us-gaap_GainLossOnSaleOfEquityInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(h)(1)(i)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 + Details
Name: | us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees. + References No definition available. + Details
Name: | us-gaap_LitigationSettlementExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The net result for the period of deducting operating expenses from operating revenues. + References No definition available. + Details
Name: | us-gaap_OperatingIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition. + References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentInProcess
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4(b)) -URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747 + Details
Name: | us-gaap_RestructuringCharges
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of unrealized gain (loss) recognized in the income statement on unsold other securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 + Details
Name: | us-gaap_UnrealizedGainLossOnSecurities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=jnj_CizHoldingsCo.Ltd.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=jnj_WesternHemisphereExcludingUSMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=jnj_AsiaPacificAfricaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_AdvancedSterilizationProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_OtherIncomeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |